How have APLMW shares performed in 2024?

Apollomics' stock was trading at $0.0250 at the beginning of the year. Since then, APLMW shares have increased by 4.0% and is now trading at $0.0260. View the best growth stocks for 2024 here .

Are investors shorting Apollomics?

Apollomics saw a decline in short interest in April. As of April 15th, there was short interest totaling 47,900 shares, a decline of 8.8% from the March 31st total of 52,500 shares. Based on an average daily volume of 11,900 shares, the days-to-cover ratio is presently 4.0 days. View Apollomics' Short Interest .

How do I buy shares of Apollomics?

Shares of APLMW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:APLMW

Apollomics (APLMW) Stock Price, News & Analysis

→ Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad)

Free APLMW Stock Alerts

$0.03

0.00 (0.00%)

(As of 04/26/2024 ET)

Compare

Today's Range: $0.03
▼
$0.03
50-Day Range: $0.01
▼
$0.04
52-Week Range: $0.01
▼
$0.13

Volume: N/A
Average Volume: 20,067 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Ownership SEC Filings Short Interest Social Media

Get Apollomics alerts:

Ad Behind the Markets

Better than Bitcoin? The Biotech Stock with 46,751% Potential

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

About Apollomics

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

APLMW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APLMW Stock News Headlines

April 25, 2024 | globenewswire.com

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

April 10, 2024 | globenewswire.com

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

April 27, 2024 | Behind the Markets (Ad)

Better than Bitcoin? The Biotech Stock with 46,751% Potential

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

March 28, 2024 | globenewswire.com

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

March 4, 2024 | globenewswire.com

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

See More Headlines

Receive APLMW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:APLMW
CUSIP: N/A
CIK: 1944885
Web: www.apollomicsinc.com
Phone: 650-209-4055
Fax: N/A
Employees: 59
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Guo-Liang Yu Ph.D. (Age 60)
Co-Founder, CEO & Exec. Chairman
Dr. Sanjeev Redkar MBA (Age 54)
Ph.D., Co-Founder, Pres & Exec. Director
Dr. Lijuan Jane Wang Ph.D. (Age 59)
Chief Scientific Officer & GM of China
Ms. Brianna MacDonald J.D.
Sr. VP & Gen. Counsel
Dr. Kin-Hung Yu M.D. (Age 61)
Chief Medical Officer
Dr. Chinglin Lai Ph.D.
Sr. VP of Biostatistics & Data Management

Key Competitors

View All Competitors

APLMW Stock Analysis - Frequently Asked Questions

How have APLMW shares performed in 2024?: Apollomics' stock was trading at $0.0250 at the beginning of the year. Since then, APLMW shares have increased by 4.0% and is now trading at $0.0260.
View the best growth stocks for 2024 here.
Are investors shorting Apollomics?: Apollomics saw a decline in short interest in April. As of April 15th, there was short interest totaling 47,900 shares, a decline of 8.8% from the March 31st total of 52,500 shares. Based on an average daily volume of 11,900 shares, the days-to-cover ratio is presently 4.0 days.
View Apollomics' Short Interest.
How do I buy shares of Apollomics?: Shares of APLMW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APLMW) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial